ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

ImmunityBio, Inc.NASDAQ: IBRX

Change in Working Capital · Q3 FY2026 · quarter ended Sep 2026

Change in working capital turns positive

Q3 FY2026 change in working capital was $9.21M, compared with -$12.33M a year earlier. Trailing-twelve-month change in working capital was -$6.11M. Over 3 fiscal years it compounded at +50.3% a year.

Context

  • Change in working capital amounted to 48.0% of revenue in FY2025, down 83.8 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near $9.21M or moves back toward the trailing-twelve-month quarterly average of -$1.53M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$9.21M+2330.3% QoQ
Last fiscal yearDec 2025
-$54.33M+179.7% YoY
LTMSep 2026
-$6.11M-88.0% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+174.7%——
1 year+179.7%——
3-year CAGR+50.3%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(54.33M) USD
Year-over-year change
-179.7%

Change in Working Capital vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -88.0% is the 9th highest of 11, against a peer median of -24.1%.
  • Change in working capital amounts to 3.3% of revenue for IBRX, versus a peer median of 29.9%.
IBRX Competitors
Change in Working Capital for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.19B EUR+189.0%-51.5%45.0%
LEGNLegend Biotech CorporationLTM Sep 2026$301.51M USD+166.3%—22.2%
MRNAModerna, Inc.LTM Sep 2026$204M USD-50.4%—8.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$103.52M USD+2.1%+19.4%447.4%
VIRVir Biotechnology, Inc.LTM Mar 2026$71.19M USD-394.2%—108.7%
IMCRImmunocore Holdings plcLTM Mar 2026$24.61M USD+2.6%-34.1%6.4%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$15.79M USD+1014.2%——
IMTXImmatics N.V.LTM Mar 2026€14.05M EUR-90.7%—37.7%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$7.29M USD-86.7%+103.2%1.9%
IBRXImmunityBio, Inc.LTM Sep 2026$6.11M USD-88.0%+50.3%3.3%
NKTXNkarta, Inc.LTM Mar 2026$3.15M USD-65.8%——
Peer median (excluding IBRX) —-24.1%-7.3%29.9%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(346.79M)(416.57M)(583.85M)(413.65M)(351.47M)
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
Deferred Income Tax00000
Stock-Based Compensation57.18M40.18M49.16M34.43M36.81M
Change in Working Capital(15.4M)(16M)3.83M(19.42M)(54.33M)
Accounts Receivables000(2.36M)(40.21M)
Inventory000(8.27M)(6.33M)
Accounts Payables00(6.48M)(3.17M)(190K)
Other Working Capital(15.4M)(16M)10.3M(5.62M)(7.6M)
Other Non-Cash Items16.35M36.62M145.44M(10.16M)48.53M
Operating Cash Flow(274.42M)(337.51M)(366.76M)(391.24M)(304.94M)
Capital Expenditures(33.56M)(78.16M)(30.58M)(6.89M)(3.85M)
Acquisitions (Net)000(1M)0
Purchases of Investments00(10.36M)(140.22M)(241.37M)
Sales of Investments0010.47M136.61M95.82M
Other Investing Activities(51.32M)105.46M0(747K)0
Investing Cash Flow(84.89M)27.3M(30.47M)(12.25M)(149.8M)
Debt Repayment338.5M174.07M451.39M96.89M1.72M
Common Stock Issued00110.4M111.36M400.78M
Common Stock Repurchased(4.06M)(616K)000
Dividends Paid00000
Other Financing Activities171.01M60.16M(3.44M)73.38M(2.27M)
Financing Cash Flow505.44M233.61M558.34M281.63M400.24M
Effect of Forex Changes48K284K(292K)(23K)15K
Net Change in Cash146.19M(76.32M)160.82M(121.88M)(54.48M)
Free Cash Flow(307.98M)(415.67M)(397.34M)(398.12M)(308.78M)

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.